229 related articles for article (PubMed ID: 24591637)
1. Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer.
Wang S; Kollipara RK; Srivastava N; Li R; Ravindranathan P; Hernandez E; Freeman E; Humphries CG; Kapur P; Lotan Y; Fazli L; Gleave ME; Plymate SR; Raj GV; Hsieh JT; Kittler R
Proc Natl Acad Sci U S A; 2014 Mar; 111(11):4251-6. PubMed ID: 24591637
[TBL] [Abstract][Full Text] [Related]
2. The ubiquitin ligase TRIM25 targets ERG for degradation in prostate cancer.
Wang S; Kollipara RK; Humphries CG; Ma SH; Hutchinson R; Li R; Siddiqui J; Tomlins SA; Raj GV; Kittler R
Oncotarget; 2016 Oct; 7(40):64921-64931. PubMed ID: 27626314
[TBL] [Abstract][Full Text] [Related]
3. Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models.
Linn DE; Bronson RT; Li Z
PLoS One; 2015; 10(3):e0120628. PubMed ID: 25780911
[TBL] [Abstract][Full Text] [Related]
4. Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells.
Mohamed AA; Tan SH; Xavier CP; Katta S; Huang W; Ravindranath L; Jamal M; Li H; Srivastava M; Srivatsan ES; Sreenath TL; McLeod DG; Srinivasan A; Petrovics G; Dobi A; Srivastava S
Mol Cancer Res; 2017 Oct; 15(10):1308-1317. PubMed ID: 28607007
[TBL] [Abstract][Full Text] [Related]
5. Context-dependent function of the deubiquitinating enzyme USP9X in pancreatic ductal adenocarcinoma.
Cox JL; Wilder PJ; Wuebben EL; Ouellette MM; Hollingsworth MA; Rizzino A
Cancer Biol Ther; 2014 Aug; 15(8):1042-52. PubMed ID: 24841553
[TBL] [Abstract][Full Text] [Related]
6. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.
Björkman M; Iljin K; Halonen P; Sara H; Kaivanto E; Nees M; Kallioniemi OP
Int J Cancer; 2008 Dec; 123(12):2774-81. PubMed ID: 18798265
[TBL] [Abstract][Full Text] [Related]
7. Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion.
Yang Y; Blee AM; Wang D; An J; Pan Y; Yan Y; Ma T; He Y; Dugdale J; Hou X; Zhang J; Weroha SJ; Zhu WG; Wang YA; DePinho RA; Xu W; Huang H
Cancer Res; 2017 Dec; 77(23):6524-6537. PubMed ID: 28986382
[TBL] [Abstract][Full Text] [Related]
8. EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer.
Zoma M; Curti L; Shinde D; Albino D; Mitra A; Sgrignani J; Mapelli SN; Sandrini G; Civenni G; Merulla J; Chiorino G; Kunderfranco P; Cacciatore A; Kokanovic A; Rinaldi A; Cavalli A; Catapano CV; Carbone GM
Nat Commun; 2021 Jul; 12(1):4147. PubMed ID: 34230470
[TBL] [Abstract][Full Text] [Related]
9. Significance of the TMPRSS2:ERG gene fusion in prostate cancer.
Wang Z; Wang Y; Zhang J; Hu Q; Zhi F; Zhang S; Mao D; Zhang Y; Liang H
Mol Med Rep; 2017 Oct; 16(4):5450-5458. PubMed ID: 28849022
[TBL] [Abstract][Full Text] [Related]
10. Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer.
Li L; Hobson L; Perry L; Clark B; Heavey S; Haider A; Sridhar A; Shaw G; Kelly J; Freeman A; Wilson I; Whitaker H; Nurmemmedov E; Oltean S; Porazinski S; Ladomery M
Br J Cancer; 2020 Sep; 123(6):1024-1032. PubMed ID: 32581342
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the deubiquitinase USP9x induces pre-B cell homeobox 1 (PBX1) degradation and thereby stimulates prostate cancer cell apoptosis.
Liu Y; Xu X; Lin P; He Y; Zhang Y; Cao B; Zhang Z; Sethi G; Liu J; Zhou X; Mao X
J Biol Chem; 2019 Mar; 294(12):4572-4582. PubMed ID: 30718275
[TBL] [Abstract][Full Text] [Related]
12. 1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion.
Washington MN; Weigel NL
Endocrinology; 2010 Apr; 151(4):1409-17. PubMed ID: 20147525
[TBL] [Abstract][Full Text] [Related]
13. Nuclear receptor ERRα and transcription factor ERG form a reciprocal loop in the regulation of TMPRSS2:ERG fusion gene in prostate cancer.
Xu Z; Wang Y; Xiao ZG; Zou C; Zhang X; Wang Z; Wu D; Yu S; Chan FL
Oncogene; 2018 Nov; 37(48):6259-6274. PubMed ID: 30042415
[TBL] [Abstract][Full Text] [Related]
14. Role of the TMPRSS2-ERG gene fusion in prostate cancer.
Tomlins SA; Laxman B; Varambally S; Cao X; Yu J; Helgeson BE; Cao Q; Prensner JR; Rubin MA; Shah RB; Mehra R; Chinnaiyan AM
Neoplasia; 2008 Feb; 10(2):177-88. PubMed ID: 18283340
[TBL] [Abstract][Full Text] [Related]
15. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
[TBL] [Abstract][Full Text] [Related]
16. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis.
Kapuria V; Peterson LF; Fang D; Bornmann WG; Talpaz M; Donato NJ
Cancer Res; 2010 Nov; 70(22):9265-76. PubMed ID: 21045142
[TBL] [Abstract][Full Text] [Related]
17. TMPRSS2-ERG fusion protein regulates insulin-like growth factor-1 receptor (IGF1R) gene expression in prostate cancer: involvement of transcription factor Sp1.
Meisel Sharon S; Pozniak Y; Geiger T; Werner H
Oncotarget; 2016 Aug; 7(32):51375-51392. PubMed ID: 27285981
[TBL] [Abstract][Full Text] [Related]
18. [The progress of TMPRSS2-ETS gene fusions and their mechanism in prostate cancer].
Guo XQ; Gui YT; Cai ZM
Yi Chuan; 2011 Feb; 33(2):117-22. PubMed ID: 21377967
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer.
Knuuttila M; Mehmood A; Mäki-Jouppila J; Ryberg H; Taimen P; Knaapila J; Ettala O; Boström PJ; Ohlsson C; Venäläinen MS; Laiho A; Elo LL; Sipilä P; Mäkelä SI; Poutanen M
Endocr Relat Cancer; 2018 Sep; 25(9):807-819. PubMed ID: 29773553
[TBL] [Abstract][Full Text] [Related]
20. Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth.
Mohamed AA; Xavier CP; Sukumar G; Tan SH; Ravindranath L; Seraj N; Kumar V; Sreenath T; McLeod DG; Petrovics G; Rosner IL; Srivastava M; Strovel J; Malhotra SV; LaRonde NA; Dobi A; Dalgard CL; Srivastava S
Cancer Res; 2018 Jul; 78(13):3659-3671. PubMed ID: 29712692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]